The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Open accessAbstract
Purpose: Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma. Patients and Methods: We employed a multiarm study design, each representing a sarcoma subtype with its own Simon optimal two-stage design. In each arm, 12 patients who received 0 to 1 prior lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor). If at least one Response Evaluation Criteria in Solid Tumors (RECIST) was observed, 25 further patients with that sarcoma subtype were accrued. Results: Between October 2005 and November 2007, 145 patients were treated; 144 were eligible for toxicity and 122 for response. Median age was 55 years; female-male ratio was 1.8:1. The median number of cycles was 3. Five of 37 patients with angiosarcoma had a partial response (response rate, 14%). This was the only arm to meet the RECIST response rate primary end point. Median progression-free survival was 3.2 months; median overall survival was 14.3 months. Adverse events (typically dermatological) necessitated dose reduction for 61% of patients. Statistical modeling in this limited patient cohort indicated sorafenib toxicity was correlated inversely to patient height. There was no correlation between phosphorylated extracellular signal regulated kinase expression and response in six patients with angiosarcoma with paired pre- and post-therapy biopsies. Conclusion: As a single agent, sorafenib has activity against angiosarcoma and minimal activity against other sarcomas. Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“A Simon optimal two-stage design was used for each arm of the study.(25) The primary end point was response rate using RECIST.”
MethodDemetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Cormier, J. N., & Pollock, R. E. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 835
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Self-citationGemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Self-citation
Cited by
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Young, R. J., Brown, N. J., Reed, M. W., Hughes, D., & Woll, P. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70023-1 · Cited by 962
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0025 · Cited by 736
Self-citationClinical management of uterine sarcomas
Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D., & Vergote, I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70226-8 · Cited by 443
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Self-citationAgulnik, M., Yarber, J. L., Okuno, S. H., von Mehren, M., Jovanovic, B. D., Brockstein, B. E., Evens, A. M., & Benjamin, R. S. (2013) · Annals of Oncology · doi:10.1093/annonc/mds237 · Cited by 389
Self-citationHensley, M. L., Blessing, J. A., DeGeest, K., Abulafia, O., Rose, P. G., & Homesley, H. D. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.024 · Cited by 365
Self-citationGrignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Malignant Peripheral Nerve Sheath Tumors
Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0328 · Cited by 354
Self-citationSoft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0078 · Cited by 297
Self-citationReview of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W., Boonsirikamchai, P., Choi, H., Wang, X., et al. (2011) · Cancer · doi:10.1002/cncr.26098 · Cited by 261
Sorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004014 · Cited by 86
Self-citationPenel-Page, M., Ray-Coquard, I., Larcade, J., Girodet, M., Bouclier, L., Rogasik, M., Corradini, N., Entz-Werle, N., Brugieres, L., Domont, J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1894-5 · Cited by 32
Chang, L.-S., Oblinger, J. L., Burns, S. S., Huang, J., Anderson, L. W., Hollingshead, M. G., Shen, R., Pan, L., Agarwal, G., Ren, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0809 · Cited by 22
“Sorafenib, which inhibits Raf and several RTKs, has only minimal activity in patients with sarcomas (13).”
BackgroundWillmer, T., Cooper, A., Sims, D., Govender, D., & Prince, S. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.11 · Cited by 21
Metadata
- Authors
- Maki, R. G., D'Adamo, D. R., Keohan, M. L., Saulle, M., Schuetze, S. M., Undevia, S. D., Livingston, M. B., Cooney, M. M., Hensley, M. L., Mita, M. M., Takimoto, C. H., Kraft, A. S., Elias, A. D., Brockstein, B., Blachère, N. E., Edgar, M. A., Schwartz, L. H., Qin, L.-X., Antonescu, C. R., & Schwartz, G. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-01
- Volume
- 27
- Issue
- 19
- Pages
- 3133-3140
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2144530818
- Cited by
- 569
- References
- 35
- FWCI
- 33.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.